News

Neurology News Network for the week ending May 23, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 22, 2020.

The data included more than 2000 brains and approximately 400 cerebrospinal fluid samples, and showed that a protein network module linked to glucose metabolism was also elevated in cerebrospinal fluid in early stages of the disease.

The director of the multiple sclerosis research unit at Ottawa Hospital discussed stem cell therapies being explored in multiple sclerosis, and which patients may be eligible for these treatments.

The study author, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of a pooled analysis of the ACHIEVE I and II studies of ubrogepant.

The drug is the first on-demand off episode treatment to be administered sublingually.

The first study to examine the impact on real-world outcomes and costs of switching patients with MS from Copaxone to Glatopa revealed few significant differences.

The chief of the Division of Neurology at Children’s Hospital of Philadelphia spoke to the need for clinical trial evidence and research for the pediatric MS population.

The data support the need to raise awareness of involuntary movements from possible tardive dyskinesia and the importance of properly screening and diagnosing patients.

The director of the Headache Center of Southern California discussed the findings of the study, as well as what these data might suggest about how onabotulinumtoxinA fits into the shifting landscape of chronic migraine care.

Findings from an analysis of a large population of individuals suggest that the blood immunoassay can predict tau and amyloid-ß pathologies, as well as differentiate and identify Alzheimer disease across the clinical spectrum.

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of interdisciplinary care and ways it can be incorporated for patients with multiple sclerosis.